Mutations in the splicing factor 3B subunit 1(SF3B1) gene located on the long arm of chromosome 2 (2q33.1) can play a role in the pathogenesis of hematologic tumors, breast cancer, and other tumors by affecting cellular functions and pathways (hemoglobin production, mitochondrial metabolism, and NF-KB pathway, etc.)(Visconte et al., 2012; Zhou et al., 2020; Liu et al., 2021) it has also been approved as a target for antitumor drugs (Cannon et al., 2024). Here, SF3B1 is linked to breast cancer.